zinc finger protein 212Genealiases: C2H2-150 · ZNF182 · ZNFC150
Q-omics provides the consensus-scored ZNF212 profile across patient tissues and cancer cell-line models. ZNF212 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ZNF212 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF212 RNA expression shows 19,893 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, HNSC, and ACC as cancer lineages where ZNF212 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF212 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF212 survival associations across molecular data types. ZNF212 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF212 RNA expression–survival associations across cancer types. High ZNF212 expression shows unfavorable associations in COAD, ACC and LGG, but favorable associations in SCLC, BRCA and THYM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ZNF212 RNA expression.
This table summarizes ZNF212 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF212. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF212 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, LUAD, BLCA and COAD. The HNSC box plot shows higher ZNF212 RNA expression in tumor versus normal tissue (log2 FC = +0.547, t-test p < 0.001).
This table shows molecular features associated with ZNF212 in patient tissues and cancer cell lines. In patient samples, ZNF212 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF212 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
